The AMPD1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma line, in which the AMPD1 gene has been disrupted to create a stable loss-of-function model. This polyclonal format preserves population heterogeneity while ensuring robust target-gene ablation, suitable for studies of nucleotide metabolism and energy homeostasis without pharmacological artifacts.
The A-549 cell line is an adherent epithelial model from a 58-year-old Caucasian male with lung adenocarcinoma, widely used to study non-small cell lung cancer biology, type II pneumocyte function, and metabolic reprogramming. Its adherent growth facilitates diverse assays, and engineering AMPD1 knockout in this background provides a physiologically relevant system to dissect purine nucleotide cycle dynamics in lung cancer.
AMPD1 catalyzes the deamination of AMP to IMP, a critical step in the purine nucleotide cycle that maintains adenine nucleotide pools and generates fumarate for the TCA cycle. The enzyme is allosterically activated by AMP, inhibited by ATP, and regulated by PKC phosphorylation, requiring zinc as a cofactor. By lowering AMP levels, AMPD1 attenuates AMPK activation, linking nucleotide catabolism to energy-sensing pathways. Knockout of AMPD1 disrupts this regulation, altering AMP/ATP ratios and potentially hyperactivating AMPK under metabolic stress.
In A-549 lung adenocarcinoma cells, AMPD1 loss impairs purine nucleotide cycling, reducing fumarate production and altering metabolic flux. This metabolic perturbation may unmask vulnerabilities to nutrient deprivation and modulate AMPK-driven proliferation and survival programs. The model thus enables investigation of how nucleotide metabolism integrates with oncogenic signaling and can serve as a platform to study parallels with myoadenylate deaminase deficiency, though in a cancer context.
Typical assays include HPLC quantification of ATP, AMP, and IMP; phospho-AMPK Western blotting; Seahorse metabolic flux analysis; and proliferation assays under metabolic stress. The polyclonal cells are also suitable for RNA-seq profiling and high-throughput drug screening to validate AMPD1 as a target. For further information and custom inquiries, please contact Ascent Research.
